Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
Conclusion: These results indicate that pembrolizumab treatment in patients older than 85 years may induce responses but is associated with a high risk of toxicity and impaired autonomy.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
More News: Dermatology | France Health | Immunotherapy | Melanoma | Skin | Skin Cancer | Study | Toxicology | Women